GHK-Cu Safety Profile

Safety Overview

Regulatory status:

• NOT FDA-approved as a drug for any indication
• Used in cosmetic products (topical serums, creams) as an ingredient
• Generally Recognized As Safe (GRAS) status does NOT apply — GHK-Cu is a cosmetic ingredient, not a food additive

Level of evidence:

• Topical cosmetic use: Moderate evidence, decades of use in skincare
• Injectable use: Minimal safety data, primarily anecdotal

Background: GHK-Cu is a naturally occurring tripeptide-copper complex (glycyl-L-histidyl-L-lysine bound to Cu²⁺) found in human plasma, saliva, and urine. Levels decline with age.

Topical Use (Cosmetic)

Safety Profile

GHK-Cu has been used in skincare products since the 1990s (notably by Neutrogena, Neova, and others).

Reported safety:

• Generally well-tolerated in concentrations of 0.05% - 3%
• Low incidence of irritation in clinical trials
• Suitable for most skin types

Topical Side Effects (Rare)

• Mild erythema (redness) in sensitive individuals
• Contact dermatitis (allergic reaction to copper or peptide) — uncommon
• Stinging sensation at application (usually resolves)

No systemic absorption expected at cosmetic concentrations.

Injectable Use (Research Chemical Context)

Critical Evidence Gap

There are NO published clinical trials assessing injectable GHK-Cu safety in humans.

Claims about systemic effects (anti-inflammatory, hair growth, tissue repair) are based on:

• In vitro studies (cell cultures)
• Animal studies (mostly rodents)
• Extrapolation from topical wound healing literature
• Anecdotal user reports

Theoretical Risks of Injectable GHK-Cu

Copper Toxicity

• Copper is an essential trace element but toxic in excess
• Copper accumulation can cause:
  • Hepatotoxicity (liver damage)
  • Neurological effects (Wilson’s disease-like syndrome)
  • Gastrointestinal distress
  • Hemolytic anemia
• Unknown: What dose of injectable GHK-Cu causes copper accumulation?
• No safety studies on chronic injectable copper-peptide use

Injection Site Reactions

• Localized pain, swelling, erythema (expected with any subcutaneous injection)
• Risk of infection if non-sterile preparation
• Potential for copper-induced local tissue irritation

Immunogenicity

• Peptide-metal complexes can theoretically trigger immune responses
• No data on antibody formation to GHK-Cu with repeated injections

Topical vs. Injectable Risk Profiles

Route	Evidence Level	Known Risks	Unknown Risks
Topical (cosmetic)	Moderate	Mild irritation, rare contact dermatitis	Long-term effects (>10 years)
Injectable (research)	Minimal	Injection site reactions, infection risk	Copper toxicity, systemic effects, immunogenicity, long-term safety

Critical point: Safety data from topical use does NOT validate injectable safety. These are entirely different exposure routes with different systemic absorption profiles.

Product Quality Concerns

GHK-Cu sold for “research purposes” is unregulated:

• No GMP manufacturing requirement
• Purity unknown — may contain copper salts, degradation products, or contaminants
• Sterility not guaranteed for injectable products
• Dosing inconsistent — vial labeling may be inaccurate
• Stability issues — copper-peptide complexes degrade over time, especially without refrigeration

Contraindications (Theoretical for Injectable Use)

Avoid injectable GHK-Cu if:

• Wilson’s disease or other copper metabolism disorders
• Liver disease (impaired copper excretion)
• Hemochromatosis or other metal storage disorders
• Pregnancy or lactation (no safety data)
• Taking copper supplements (risk of cumulative toxicity)

What We Don’t Know

Question	Status
Safe dose range for injectable use	Unknown
Frequency and duration limits	Unknown
Copper accumulation over time	Not studied
Long-term systemic effects	Unknown
Interaction with other supplements/medications	Unknown
Carcinogenicity (chronic use)	Not studied

Current Evidence Summary

Established:

• GHK-Cu is safe for topical cosmetic use at concentrations up to ~3%
• Naturally occurring in human body at low concentrations

Not established:

• Safety of injectable GHK-Cu at any dose
• Systemic therapeutic effects in humans (mostly rodent data)
• Long-term safety of chronic copper-peptide supplementation

This safety information reflects available evidence as of 2026. Injectable GHK-Cu has NOT been studied for safety in human clinical trials. Topical safety data does not validate injectable use. This is not medical advice.